Rodman & Renshaw comments on the aftershock of AstraZeneca's (NYSE: AZN) MedImmune (Nasdaq: MEDI) acquisition at a 21% premium to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE